News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
Oct 20, 2025
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and AlliancesOct 14, 2025
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older AdultsJun 17, 2025
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine CandidatesMar 24, 2025
Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019Oct 29, 2024
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK’s AREXVYJun 18, 2024
Clover Announces Positive Preliminary PhaseⅠResults for Bivalent RSV Vaccine Candidate SCB-1019 in Older AdultsApr 08, 2024
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult CohortDec 29, 2023
Clover Announces Positive PhaseⅠResults for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)Dec 13, 2023
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine CandidateNov 07, 2023
Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil
